Learn
Research-backed guides on CBD pharmacology, medication safety, and condition-specific evidence. Every article cites primary literature — PubMed where available.
CBD inhibits CYP3A4, CYP2C9, CYP2C19, CYP2D6, and UGT enzymes — the same pathways that clear most prescription medications. Per-drug evidence, severity ratings, and prescriber questions.
Warfarin
INR monitoring required
Benzodiazepines
Geffrey 2015 — clobazam +60%, N-CLB +500%
SSRIs
Anderson 2022 — CYP2D6 pharmacogenomics matter
Statins
CYP3A4 — simvastatin / atorvastatin highest risk
Blood pressure medications
CYP3A4 + direct BP-lowering signal (Jadoon 2017)
Plaquenil (hydroxychloroquine)
CYP2D6 + CYP3A4 dual pathway
NSAIDs
OTC occasional: low risk; chronic Rx: discuss with prescriber
Levothyroxine
Absorption timing; TSH monitoring on long-term CBD
Gabapentin
Not CYP-mediated; additive sedation is the concern
Tylenol (acetaminophen)
UGT overlap + AM404; chronic high-dose use warrants awareness
CYP450 mechanism explainer
How enzyme inhibition works — plain English
What the research says — and doesn't say — about CBD for specific autoimmune and inflammatory conditions. Honest evidence framing; no therapeutic claims.
Hashimoto's thyroiditis
No clinical trials for Hashimoto + CBD; ECS mechanism and safety context
Psoriatic arthritis
Vela 2022 RCT — null result for PsA specifically; honest framing
Ankylosing spondylitis
No AS-specific CBD trial; IL-17/IL-23 axis + Fitzcharles 2016 survey context
Hip osteoarthritis
Pramhas 2023 was knee-specific; topical CBD cannot reach hip joint
How-to guides
Practical protocols for using CBD safely and effectively.
CBD and joint pain: evidence by condition, topical vs oral, medication safety
Pillar hub — Pramhas 2023 RCT anchor; Vela 2022 null; 6 condition evidence table
Inflammaging and CBD: the Franceschi framework and what the evidence supports
Franceschi 2018 framework; NF-κB/Nrf2/CB2; honest 'no human RCT' disclosure
CBD and inflammation: the mechanism explainer
NF-κB, CB2, Th1/Th17, FAAH — preclinical strong, human evidence condition-specific
CBD and chronic pain: what the evidence actually shows
Pain type framework: nociceptive, neuropathic, nociplastic — Pramhas 2023 + Mucke 2018
CBD science & dosing: how it works, bioavailability, and dosing
ECS, FAAH, inverted-U dose-response (Linares 2019), food effect (Birnbaum 2019 4–5×)
CBD dosing for autoimmune conditions
Start at 10mg, not 25mg — drug interactions come first
CBD for sleep and stress: pillar hub
Shannon 2019 + Bergamaschi 2011; 5-HT1A not GABA-A; cortisol/HPA axis bridge
CBD and sleep
Shannon 2019 n=72 — continuity over initiation; not a sedative
CBD and anxiety
Bergamaschi 2011 RCT + Shannon 2019 — acute model stronger than chronic GAD
CBD titration protocol
General start low, go slow protocol — Linares 2019
How to read a CBD certificate of analysis
Potency, pesticides, heavy metals, and what to look for
CBD for masters athletes
Recovery, inflammation, and WADA compliance